Pinealon

ID: pinealon

Aliases: PINEALON, EDR peptide, Glu-Asp-Arg

Type: compound

Route/form: regional/research short peptide context; route varies and is not US-approved

Status: research_or_regional

Evidence level: early human

Best data tier: early human

Support scope: human, non-human/mechanistic

Source types: early_human, mechanistic, preclinical

Linked sources: 3

Broad outcomes: Brain / mood / sleep, Longevity / mitochondrial / redox

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• gene-expression regulation hypothesis
• free-radical suppression in cell models
• neuroprotective peptide-bioregulator claims

Optimization domains

• brain
• longevity
• neuroprotection
• aging

Research basis

• Cell and mechanistic EDR literature gives a rationale for neuroprotective/aging claims.

Limits, risks, and missing evidence

• Human evidence quality and applicability are limited.
• Do not treat as equivalent to approved neurorehabilitation drugs or robust cognitive enhancers.

Risk flags

• regional bioregulator literature
• weak human context
• unapproved context
• identity uncertain

Linked papers, labels, and reviews

1. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
   preclinical / pubmed_pinealon_cell_viability_2011
   Cell/organotypic model anchor for Pinealon claims.
2. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer disease
   mechanistic / pubmed_pinealon_edr_alz_2020
   Mechanistic EDR/Pinealon gene-expression paper.
3. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission
   early_human / pubmed_pinealon_polymorbidity_2015
   Older regional human source; interpret cautiously due limited accessibility/generalizability.